Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Intermittent Fasting and Prevention of Diabetic Retinopathy: Where Do We Go From Here?

  1. Martin Haluzík1,2,3⇑ and
  2. Miloš Mráz2,3
  1. 1Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
  2. 2Diabetology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
  3. 3Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University and General University Hospital, Prague, Czech Republic
  1. Corresponding author: Martin Haluzík, halm{at}ikem.cz.
Diabetes 2018 Sep; 67(9): 1745-1747. https://doi.org/10.2337/dbi18-0022
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Type 2 diabetes represents one of the most significant global health threats of the 21st century owing to its constantly increasing prevalence and long-term debilitating complications (1). In addition to accelerated macrovascular disease in poorly controlled diabetes that is responsible for increased cardiovascular morbidity and mortality, microvascular complications, such as diabetic nephropathy, neuropathy, and retinopathy, cause a significant burden and may markedly impair not only life expectancy but also quality of life of patients with diabetes (2). Diabetic retinopathy is the most common cause of blindness in developed countries and one of the most feared diabetes complications (3).

Significant progress has been made in our understanding of the etiopathogenesis of type 2 diabetes with numerous novel contributing mechanisms identified in the past couple of years (4). Both experimental and clinical studies have demonstrated that gut represents a vital organ with respect to regulation of glucose metabolism and modulation of the risk of type 2 diabetes development (5). Multiple facets of the gut–glucose metabolism interconnection have been uncovered in particular by studying the changes induced by weight loss associated with bariatric surgery or endoscopic methods mimicking bariatric surgery. The possible mechanisms of gut-driven improvements in glucose metabolism after surgical or endoscopic interventions include restriction of food amount, enhanced passage of chymus into distal parts of small intestine with subsequent modification of gastrointestinal hormones and bile acid secretion, neural mechanisms, changes in gut microbiota, and many others (6). Studies have shown that type 2 diabetes is accompanied by impaired microbiota composition and its decreased diversity, with subsequent modulations of energy yield from intestinal content, metabolization of bile acids, intestinal permeability, and other characteristics of the gut (7).

Energy restriction is an important therapeutic approach leading to improvement of glucose control in patients with type 2 diabetes. Nevertheless, the compliance of patients to long-term hypocaloric diet is limited, and other approaches more acceptable from the patient perspective are needed. Intermittent fasting represents an alternative and more physiological way to prevent deleterious effects of chronic excess of food intake. This approach enables the combination of energy-restricted and unrestricted days, which is better accepted by the majority of patients. In both experimental and clinical studies, intermittent fasting has been shown to improve insulin sensitivity and glucose control along with modest decreases in body weight (8). The long-term effects of intermittent fasting on glucose control and diabetes complications are largely unknown.

In this issue of Diabetes, Beli et al. (9) bring an important body of evidence to the puzzle of possible effects of intermittent fasting on the reduction of microvascular diabetes complications. They used the genetic model of severe type 2 diabetes leptin receptor–deficient db/db mice to study the effects of intermittent fasting versus ad libitum feeding on long-term survival, metabolic parameters, and diabetic retinopathy. They found that, despite no significant effects of intermittent fasting on body weight or glucose control, this regimen resulted in longer survival and reduction of diabetic retinopathy end points, including acellular capillaries and leukocyte infiltration, in db/db mice. They further demonstrated that intermittent fasting markedly altered gut microbiota composition with increased levels of Firmicutes and decreased Bacteroidetes and Verrucomicrobia along with improvement in gut structure, including increased gut mucin, goblet cell number, and villi length and reduced peptidoglycan, suggesting improved gut barrier. Most importantly, intermittent fasting increased concentrations of tauroursodeoxycholate (TUDCA), a secondary bile acid with neuroprotective properties (10). The authors have demonstrated the presence of TUDCA TGR5 receptors in neural cells of the retina, and pharmacological activation of TGR5 by potent semisynthetic bile acid derivative INT-767 (11) prevented diabetic retinopathy in another diabetic mouse model. This led the authors to the conclusion that intermittent fasting modified the gut microbiota toward species that produce TUDCA, which subsequently prevented retinopathy by TGR5 activation in retinal neural cells. The hypothetic mechanism of action of intermittent fasting on diabetic retinopathy is depicted in Fig. 1.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Potential mechanisms of diabetic retinopathy improvement by intermittent fasting.

Overall, the study brings a very interesting concept that is well supported by provided data. Yet as with any good research, although some of the questions were answered, several more emerged. As the authors focused mostly on microbiota and changes in secondary bile acids as possible mechanisms of retinopathy improvements, it is not clear if other changes induced by intermittent fasting also contributed to the favorable outcomes. Previous studies have shown that intermittent fasting can improve autophagy, reduce oxidative stress and advanced glycation end products, modulate endocrine function of adipose tissue toward increased production of adiponectin and other “healthy” adipokines, and have multiple other beneficial effects (12). Further studies are necessary to dissect the possible contribution of these other potentially beneficial mechanisms.

As the TUDCA TGR5 receptors are present in neural cells, it is tempting to speculate that intermittent fasting could also have the potential to improve other diabetic microvascular complications, in particular diabetic neuropathy. The most important question, however, is whether and to what degree could such a concept be extrapolated to humans. Although changes in gut microbiota have been studied in numerous clinical situations, it is currently not known if intermittent fasting alters gut microbiota composition and/or circulating bile acid levels in humans. It is also quite difficult to predict whether intermittent fasting could be successfully applied in long-term clinical studies or, optimally, in routine clinical practice. Another interesting possibility could be to ameliorate diabetic retinopathy by administration of TUDCA or its synthetic agonists.

In summary, the study by Beli et al. (9) offers a completely new potential mechanism of improving diabetic retinopathy with dietary modifications without significant changes in glucose control or body weight. Such concepts may apply not only to dietary approaches but also to changes in gut microbiota composition induced by bariatric surgery or endoscopic methods for diabetes treatment. Finally, it is tempting to speculate that differences in gut microbiota may explain why some of the patients with diabetes are more prone to developing diabetic retinopathy as compared with others while having the same control of diabetes and other risk factors. These data open up new avenues for clinical research aimed at delaying or preventing diabetic retinopathy that could markedly alter the fate of many patients with diabetes.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 1867.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. O’Rahilly S
    . Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997;314:955–959
    OpenUrlFREE Full Text
  2. ↵
    1. Chatterjee S,
    2. Khunti K,
    3. Davies MJ
    . Type 2 diabetes. Lancet 2017;389:2239–2251
    OpenUrl
  3. ↵
    1. Hammes HP
    . Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia 2018;61:29–38
    OpenUrlPubMed
  4. ↵
    1. Defronzo RA
    . Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–795
    OpenUrlFREE Full Text
  5. ↵
    1. Holst JJ,
    2. Gromada J
    . Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199–E206
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Haluzík M,
    2. Kratochvílová H,
    3. Haluzíková D,
    4. Mráz M
    . Gut as an emerging organ for the treatment of diabetes: focus on mechanism of action of bariatric and endoscopic interventions. J Endocrinol 2018;237:R1–R17
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bouter KE,
    2. van Raalte DH,
    3. Groen AK,
    4. Nieuwdorp M
    . Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. Gastroenterology 2017;152:1671–1678
    OpenUrl
  8. ↵
    1. Mattson MP,
    2. Longo VD,
    3. Harvie M
    . Impact of intermittent fasting on health and disease processes. Ageing Res Rev 2017;39:46–58
    OpenUrl
  9. ↵
    1. Beli E,
    2. Yan Y,
    3. Moldovan L, et al
    . Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes 2018;67:1867–1879
    OpenUrlCrossRef
  10. ↵
    1. Gronbeck KR,
    2. Rodrigues CM,
    3. Mahmoudi J, et al
    . Application of tauroursodeoxycholic acid for treatment of neurological and non-neurological diseases: is there a potential for treating traumatic brain injury? Neurocrit Care 2016;25:153–166
    OpenUrl
  11. ↵
    1. Rizzo G,
    2. Passeri D,
    3. De Franco F, et al
    . Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 2010;78:617–630
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Golbidi S,
    2. Daiber A,
    3. Korac B,
    4. Li H,
    5. Essop MF,
    6. Laher I
    . Health benefits of fasting and caloric restriction. Curr Diab Rep 2017;17:123
    OpenUrl
View Abstract
PreviousNext
Back to top
Diabetes: 67 (9)

In this Issue

September 2018, 67(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Intermittent Fasting and Prevention of Diabetic Retinopathy: Where Do We Go From Here?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intermittent Fasting and Prevention of Diabetic Retinopathy: Where Do We Go From Here?
Martin Haluzík, Miloš Mráz
Diabetes Sep 2018, 67 (9) 1745-1747; DOI: 10.2337/dbi18-0022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Intermittent Fasting and Prevention of Diabetic Retinopathy: Where Do We Go From Here?
Martin Haluzík, Miloš Mráz
Diabetes Sep 2018, 67 (9) 1745-1747; DOI: 10.2337/dbi18-0022
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.